Oculis Completes Patient Randomization in PREDICT-1 Dry Eye Trial
Oculis Holding AG (OCS) has finished randomizing 176 patients in its registrational PREDICT-1 clinical trial. The study evaluates Licaminlimab, an investigational treatment designed for patients with dry eye disease who carry the TNFR1 genotype. Approximately two-thirds of the enrolled participants possess this specific genetic marker.
The trial uses a genotype-guided approach to focus on patients who are most likely to respond positively to treatment. Licaminlimab previously demonstrated a reduction in symptoms during Phase 2 clinical testing. The primary endpoint for the current trial evaluates symptom changes after 29 days of treatment, offering a short window to measure initial efficacy.
Investors and clinical observers now look ahead to late 2026, when topline results from the trial are expected to be released. Shares of Oculis Holding AG traded down 1.49% to $7.29 following the announcement.
Key points
- Oculis completed randomization of 176 patients in the PREDICT-1 registrational study for dry eye disease.
- About two-thirds of trial participants carry the targeted TNFR1 genotype.
- The primary study endpoint evaluates symptom relief at Day 29 of treatment.
- Topline clinical data from the trial are expected near the end of 2026.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the PREDICT-1 trial evaluating?
The PREDICT-1 trial evaluates Licaminlimab as a precision medicine treatment for TNFR1-mediated dry eye disease.
When will topline data from the PREDICT-1 trial be available?
Topline results from the trial are expected around year-end 2026.
How many patients are enrolled in the Oculis PREDICT-1 trial?
The trial completed randomization with 176 patients, roughly two-thirds of whom carry the TNFR1 genotype.